Galapagos and Arthrogen enter target discovery alliance
Galapagos NV announced that its service division BioFocus has entered into a three-year target discovery alliance with Arthrogen BV, a joint venture of the Dubai Bone & Joint Center and the Academic Medical Center in Amsterdam. The alliance focuses on identifying novel targets for gene therapy applications in rheumatoid arthritis. Under the terms of the agreement, BioFocus will extend its SilenceSelect® collection with new gene sets, set up cellular assays and screen the expanded SilenceSelect collection in the assays. The human protein targets identified in the screens will then be characterized and validated. In return, Galapagos will receive from Arthrogen an upfront payment and R&D funding and will be eligible for development milestones. Should all criteria on a target be achieved, revenues for Galapagos with respect to such target may exceed EUR 7.5 million. Additionally, Galapagos is entitled to receive royalties on any marketed products that may arise from the alliance.
The SilenceSelect target discovery platform is based on adenoviruses that efficiently introduce human gene sequences into a wide variety of human cells to knock-down specific proteins. High-throughput assays that represent a selected human disease state are then used to functionally select for those proteins that have a causative effect in those models of human disease. After rigorous validation of these protein targets, they form the basis for the development of novel drugs.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
